Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Oncogene. 2022 Apr 19;41(21):2958–2972. doi: 10.1038/s41388-022-02311-z

Fig. 7. Altered expression of cancer stem cell markers following loss of KDM5B.

Fig. 7

A Expression analysis of CSC surface markers CD24, CD44, CD15, and CD133 was analyzed using flow cytometry and FlowJo software. CD24, CD44, CD15, and CD133 expression profiles are shown for control (shLuc; black) and shKDM5B (red) K562 leukemia, LOX IMVI and UACC-62 melanoma, IGROV1, OVCAR-3, and OVCAR-4 ovarian cancer cells, and CAKI-1 renal cancer cells. B t-SNE projection analysis defines CD24+, CD44+, CD15+, and CD133+ populations.